Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the
treatment of cognitive impairment associated with schizophrenia and other psychiatric …

The structure-based design, synthesis, and biological evaluation of a new pyrazole series of
irreversible KAT II inhibitors are described herein. The modification of the inhibitor scaffold …

A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of
kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and …

Introduction CD44 is a cell adhesion molecule believed to play a critical role in T cell and
monocyte infiltration in the inflammatory process. The reduction of CD44 expression or its …

Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and
abnormalities in KYNA levels have been associated with various central nervous system …

A series of kynurenine aminotransferase II (KAT II) inhibitors has been developed replacing
the hydroxamate motif with a bioisostere. Triazolinones or triazoles have proven to be …

Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a
therapeutic strategy for neurologic and psychiatric diseases due to the fundamental role of …

The discovery of D1 subtype-selective agonists with drug-like properties has been an
enduring challenge for the greater part of 40 years. All known D1-selective agonists are …

The dopamine D1 receptor is a G protein-coupled receptor that regulates intracellular signaling
via agonist activation. Although the number of solved GPCR X-ray structures has been …

p59fynT is a protein tyrosine kinase in the src family that has been associated with and believed
to function in the signaling of many receptors, including the T-cell receptor. A role for the …